Loading…
Cardiff Oncology, Inc. is projected to decline to $0.753 by 2027, a -12% move from its current price of $0.8554. CRDF is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.8213 | $0.8552 | $0.8906 | -0.02% |
| Aug 6 | $0.8074 | $0.855 | $0.9054 | -0.04% |
| Aug 7 | $0.7969 | $0.8548 | $0.917 | -0.07% |
| Aug 8 | $0.7882 | $0.8546 | $0.9268 | -0.09% |
| Aug 9 | $0.7805 | $0.8545 | $0.9355 | -0.11% |
| Aug 10 | $0.7736 | $0.8543 | $0.9434 | -0.13% |
| Aug 11 | $0.7673 | $0.8541 | $0.9507 | -0.15% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.7673 | $0.8541 | $0.9507 | -0.15% |
| Week 2 | $0.7329 | $0.8528 | $0.9923 | -0.31% |
| Week 3 | $0.7072 | $0.8515 | $1.03 | -0.46% |
| Week 4 | $0.6862 | $0.8502 | $1.05 | -0.61% |
| Week 5 | $0.668 | $0.8489 | $1.08 | -0.77% |
| Week 6 | $0.6519 | $0.8475 | $1.10 | -0.92% |
| Week 7 | $0.6374 | $0.8462 | $1.12 | -1.07% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for cancer in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
The clinical program includes indications such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for metastatic colorectal cancer in patients with KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm trial in KRAS-mutated metastatic colorectal cancer.
Cardiff Oncology, Inc. was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology was founded in 1999 and is headquartered in San Diego, California.
CRDF is the stock ticker for Cardiff Oncology, currently trading at $0.8269 per share. The company has a market cap of $64.33M and ranks 4217 by market capitalization.
The current sentiment is NEUTRAL with RSI14 at 30, SMA50 at $1.40 and SMA200 at $1.92. The 30-day range runs from $0.6075 to $1.13, with support at $0.84 and resistance at $1.59. Annualized volatility is 90%.
Forecasts show mixed near-term results but longer-term upside, with 2026 min $0.8269, avg $0.8269, max $0.9577 (ROI 0, NEUTRAL) and higher potential later, including 2030 avg $0.9601 and 2050 avg $2.93 (ROI 254.8, BULLISH).
A major floor 45.4% below — a decisive break under it would weaken the trend.
The nearest floor, 5.3% below — buyers have tended to step in here.
The nearest ceiling, 57.8% above — a clean break opens room to run.
A major ceiling 126.8% above — clearing it would confirm fresh momentum.
Key CRDF support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CRDF market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.836 | Buy | $0.8454 | Buy |
| MA 10 | $0.839 | Buy | $0.8768 | Sell |
| MA 20 | $1.01 | Sell | $0.9788 | Sell |
| MA 50 | $1.29 | Sell | $1.21 | Sell |
| MA 100 | $1.50 | Sell | $1.46 | Sell |
| MA 200 | $1.88 | Sell | $1.80 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 33.22 | Neutral |
| Stoch RSI (14) | 33.12 | Neutral |
| CCI (20) | -47.66 | Neutral |
| Williams %R (14) | -90.00 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -3.37 | Sell |
| Bollinger %B (20,2) | 0.33 | Neutral |
| Stochastic %K (14) | 10.00 | Buy |
| TRIX (15) | -1.68 | Sell |
| Awesome (5,34) | -0.29 | Sell |
| Ultimate (7,14,28) | 36.89 | Neutral |
| Momentum (10) | -0.02 | Sell |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 0.83 | Buy |
| ADX (14) | 31.60 | Sell |
| ATR (14) | 0.04 | Info |
The 30-day picture centers on a modest trading band: the 30-day range is $0.6075 to $1.13. RSI14 is 30, SMA50 is $1.40 and SMA200 is $1.92, illustrating a neutral technical stance.
Support is at $0.84 and resistance at $1.59, defining near-term limits for price action.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.81 | $0.8554 | $1.01 | 0% | Neutral | |
| $0.5743 | $0.753 | $1.06 | -12% | Neutral | |
| $0.5652 | $0.7746 | $1.15 | -9% | Neutral | |
| $0.6273 | $0.8921 | $1.38 | +4% | Neutral | |
| $0.6909 | $1.02 | $1.62 | +19% | Neutral | |
| $0.7652 | $1.16 | $1.90 | +36% | Bullish | |
| $0.7721 | $1.20 | $2.03 | +41% | Bullish | |
| $0.6945 | $1.11 | $1.92 | +30% | Bullish | |
| $0.6992 | $1.15 | $2.02 | +34% | Bullish | |
| $0.6562 | $1.11 | $1.98 | +29% | Bullish | |
| $0.9469 | $1.80 | $3.49 | +110% | Bullish | |
| $1.47 | $3.28 | $7.14 | +283% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.81 | $0.8554 | $1.03 | +0.00% |
| September 2026 | $0.6864 | $0.8232 | $1.02 | -3.77% |
| October 2026 | $0.6919 | $0.8384 | $1.06 | +1.85% |
| November 2026 | $0.6834 | $0.8352 | $1.07 | -0.39% |
| December 2026 | $0.6344 | $0.7813 | $1.01 | -6.45% |
Click any year to see its month-by-month CRDF forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CRDF to range from $0.81 to $1.01 through 2026. The $0.8554 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The CRDF price prediction for 2027 points to an average of $0.753 (low $0.5743, high $1.06) — a potential decline of -12% on today's $0.8554. A consolidation phase looks the most probable path here.
In 2028, CRDF is projected to trade between $0.5652 and $1.15, averaging $0.7746 — a potential decline of -9% from today's $0.8554. That is up +3% on the projected 2027 average. Price action looks broadly range-bound.
Cardiff Oncology, Inc.'s 2029 outlook centres on $0.8921, within a $0.6273 to $1.38 range. That is up +15% on the projected 2028 average. That marks a +4% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, CRDF could reach as high as $1.62, with a base case around $1.02 and support toward $0.6909 — roughly +19% from $0.8554. Price action looks broadly range-bound.
Expect CRDF to range from $0.7652 to $1.90 through 2031. The $1.16 average target implies a +36% move from current prices. That is up +14% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The CRDF price prediction for 2032 points to an average of $1.20 (low $0.7721, high $2.03) — a potential gain of +41% on today's $0.8554. Momentum favours further upside here.
In 2033, CRDF is projected to trade between $0.6945 and $1.92, averaging $1.11 — a potential gain of +30% from today's $0.8554. That is -8% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
Cardiff Oncology, Inc.'s 2034 outlook centres on $1.15, within a $0.6992 to $2.02 range. That is up +3% on the projected 2033 average. That marks a +34% change versus current levels. Momentum favours further upside here.
By 2035, CRDF could reach as high as $1.98, with a base case around $1.11 and support toward $0.6562 — roughly +29% from $0.8554. Buyers look set to stay in control over this stretch.
Expect CRDF to range from $0.9469 to $3.49 through 2040. The $1.80 average target implies a +110% move from current prices. That is up +62% on the projected 2035 average. Momentum favours further upside here.
The CRDF price prediction for 2050 points to an average of $3.28 (low $1.47, high $7.14) — a potential gain of +283% on today's $0.8554. Buyers look set to stay in control over this stretch.
Investing $1,000 in CRDF today (≈ 1,169.043722 CRDF) could be worth
$3,830.74
+$2,830.74 (+283%) by 2050 · US Dollar
Based on the average projected CRDF price of $3.28 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CRDFwould be worth at today's price.
$1,000 invested in CRDF on Jul 31, 2025 (≈ 421.940949 CRDF) would be worth
$360.93
-$639.07 (-63.9%) today · 0.36× · US Dollar
Based on a CRDF entry price of $2.37 vs. today's $0.8554.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.83 | $1,030.6 | +3.1% |
| 1 month ago | $1.29 | $663.1 | -33.7% |
| 3 months ago | $1.71 | $500.23 | -50.0% |
| 6 months ago | $1.71 | $500.23 | -50.0% |
| 1 year ago | $2.37 | $360.93 | -63.9% |
| All time (5.0y) ago | $5.15 | $166.1 | -83.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CRDF forecast.
Our base-case forecast reaches $1.70 around 2040.
Implied market cap at $1.70: $132.25M
The multi-year forecast points to higher potential beyond 2026. The 2026 forecast shows min $0.8269, avg $0.8269, max $0.9577, ROI 0, sentiment NEUTRAL. By 2030 the avg is $0.9601 with a max of $1.60 and ROI of 16.1, followed by 2031 avg $1.09 and max $1.86 with ROI 31.4 (BULLISH), and 2032 avg $1.12 and max $1.99 ROI 36 (BULLISH).
The sequence continues with 2033 avg $1.03 max $1.87 ROI 25.1, 2034 avg $1.03 max $1.91 ROI 24.6, and 2035 avg $0.9838 max $1.86 ROI 19 (NEUTRAL). The forecast then extends to 2040 with avg $1.64 max $3.39 ROI 98.3 (BULLISH) and 2050 with avg $2.93 max $6.75 ROI 254.8 (BULLISH).
These figures imply a long-run uptrend with substantial upside in later years, tempered by notable volatility. These are estimates, not guarantees.
Tap a question to reveal the answer.
2030 avg price is $0.9601 with a max of $1.60 and a min of $0.6244; ROI 16.1; sentiment NEUTRAL.
Near-term forecasts are NEUTRAL in 2026 with 0 ROI and later years show bullish potential, e.g., 2031 avg $1.09 (ROI 31.4) and 2050 avg $2.93 (ROI 254.8). These are estimates, not guarantees.
Yes, the forecast max by 2050 is $6.75 with an avg of $2.93 and min of $1.32, indicating potential to rise above $2 over the horizon.
The current price is $0.8269 per share.
The forecast shows high volatility with an annualized volatility of 90% and wide 30-day price range ($0.6075 to $1.13), plus a mixture of neutral and bullish years.
Cardiff Oncology, Inc. Community Discussion
0Share your Cardiff Oncology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.